The January 10, 2017, article by Nogova et al, entitled “Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic ...
California based clinical-stage biopharmaceutical concern focused on the development of precision medicines that leverage its expertise in fibroblast growth factor receptor (FGFR) biology to treat ...
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...
The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback